Loading
BridgeBio Pharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 Jun 2025.
BridgeBio Pharma, Inc.: what insiders have been doing
Every trade that managers of BridgeBio Pharma, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Palo Alto, United States. It was founded in 2015. The last twelve months, up to 18 October 2026, brought 112 filings signed by 22 insiders.
No insider bought on the market over the period, while 7 insiders filed 54 sales totalling €40.8M. The totals do not cover 6 filings with an undisclosed amount. The largest single trade was a sale of €8.9M by Cook Jennifer E., published on 13 July 2026, equal to 0.079% of the market capitalisation.
With 112 filings in twelve months, the company is more active than the median of 19 filings across the 5,811 companies we follow on the same exchange. Our records for BridgeBio Pharma, Inc. go back to 2021, with 12 purchases and 95 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 502.1 m USD and net income at -732.9 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
257
Thresholds
n/a
Buy Volume
€2M
12 ops. · all time
Sell Volume
€880M
95 ops. · all time
Who traded when
BuySaleNeil Kumar53 sales
Jennifer E. Cook6 sales
Maricel Apuli5 sales
Mccormick Frank3 sales
Valantine Hannah3 sales
KKR Genetic Disorder L.P.2 sales
+6 other insiders
Since the insiders bought
- +25.7%Entry US$11.14 · Close at T+365 US$14.00
- +25.9%Entry US$10.76 · Close at T+365 US$13.55
- -51.6%Entry US$16.29 · Close at T+365 US$7.88
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BridgeBio Pharma, Inc. Strong Buy (bullish), based on 22 analysts. Average price target: US$108.27.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$67.13
Analyst consensus
22 analystsStrong buy
US$80.00Target US$108.27(+61%)US$156.00
Income statement
RevenueUS$502.1M
Gross profitUS$481.1M96% margin
EBITDA-US$548.8M-109% margin
Net income-US$724.9M-97.0% margin
Valuation
PER (forward)-262.9x
Beta0.97
Balance sheet & cash
Market capUS$13.1B
Total debtUS$1.9B
Free Cash Flow-US$455.5M
Profitability & ownership
ROA-26.0%
% insiders3.9%
% institutions99.6%
Last declaration on 21 September 2026
Declarations257 total
8,721 shares@ US$69.01360.0047% mcap1.1% of flowCommon StockSEC:0001470831-26-000897:0
1,279 shares@ US$69.56960.0007% mcap0.2% of flowCommon StockSEC:0001470831-26-000897:1
1,800 shares@ US$84.68670.0012% mcap0.3% of flowCommon StockSEC:0001470831-26-000848:5
1,900 shares@ US$81.14940.0012% mcap0.3% of flowCommon StockSEC:0001470831-26-000848:0
17,279 shares@ US$82.21040.011% mcap2.5% of flowCommon StockSEC:0001470831-26-000848:1
14,602 shares@ US$82.99220.0093% mcap2.1% of flowCommon StockSEC:0001470831-26-000848:2
1,199 shares@ US$83.77320.0008% mcap0.2% of flowCommon StockSEC:0001470831-26-000848:3
8,100 shares@ US$83.85880.0052% mcap1.2% of flowCommon StockSEC:0001470831-26-000848:4
100 shares@ US$85.650.0001% mcap0.0% of flowCommon StockSEC:0001470831-26-000848:6
30,000 shares@ US$82.980.019% mcap100.0% of flowCommonSEC144:0001950047-26-008424
34,980 shares@ US$79.890.021% mcap100.0% of flowCommonSEC144:0001950047-26-008337
33,544 sharesCommon StockSEC:0001470831-26-000836:0
19,599 sharesCommon StockSEC:0001470831-26-000836:1
11,554 sharesCommon StockSEC:0001470831-26-000836:2
6,520 sharesCommon StockSEC:0001470831-26-000836:3
36,237 shares@ US$79.860.022% mcap5.1% of flowCommon StockSEC:0001470831-26-000836:4
22,781 shares@ US$79.860.014% mcap16.5% of flowCommon StockSEC:0001470831-26-000837:0
4,714 shares@ US$79.860.0029% mcap18.0% of flowCommon StockSEC:0001470831-26-000835:0
21,501 shares@ US$79.860.013% mcap91.8% of flowCommonSEC144:0001950047-26-008246
2,000 shares@ US$80.060.0012% mcap7.7% of flowCommon StockSEC:0001470831-26-000745:0
36,167 shares@ US$84.000.024% mcap18.0% of flowCommon StockSEC:0001470831-26-000708:3
112,422 shares@ US$90.000.079% mcap60.0% of flowCommon StockSEC:0001470831-26-000708:4
19,000 shares@ US$8.450.0012% mcap1.0% of flowCommon StockSEC:0001470831-26-000708:0
112,422 shares@ US$29.000.025% mcap19.3% of flowCommon StockSEC:0001470831-26-000708:1
17,167 shares@ US$16.750.0022% mcap1.7% of flowCommon StockSEC:0001470831-26-000708:2
25 of 257 declarations
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (ticker: BBIO) is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States. Founded in 2015, BridgeBio was built around a focused thesis: apply genetic medicine and precision development to create therapies for patients with serious inherited diseases, especially where unmet medical need remains high. The company is headquartered in Palo Alto, California, placing it in the center of the U.S. biotech ecosystem.
BridgeBio’s operating model is somewhat distinctive. Rather than relying on a single drug program, it has developed a portfolio structure that includes wholly owned programs, specialized subsidiaries, and strategic investments. This gives the company exposure to multiple scientific shots on goal, spanning early discovery through late-stage development and, more recently, commercial execution. For investors, that model can create optionality, but it also means capital allocation discipline and clinical execution are critical.
Read moreShow less
BridgeBio has moved into the commercial stage with Attruby (acoramidis), its first FDA-approved product. The drug was approved in November 2024 in the United States for cardiomyopathy of wild-type or hereditary transthyretin amyloidosis in adults. Attruby is strategically important because it transforms BridgeBio from a development-stage biotech into a multi-product company with recurring product revenue potential. Beyond Attruby, the company continues to highlight a late-stage pipeline that includes low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9.
In competitive terms, BridgeBio is positioned as a precision-medicine platform targeting genetically defined diseases. That niche can be attractive because patient populations are often well characterized, clinical development pathways may be more focused, and successful assets can command meaningful commercial value despite smaller addressable markets. At the same time, the company remains exposed to the usual biotech risks: regulatory timing, trial-readout volatility, commercialization execution, and financing needs.
BridgeBio’s geographic footprint is still predominantly U.S.-centered, particularly for research, regulatory activities, and the commercialization of Attruby in the United States. Recent milestones have included strengthening the balance sheet, scaling the U.S. commercial launch, and reporting multiple positive late-stage clinical updates in 2025-2026 that support the company’s broader genetic-medicine strategy. For French, Belgian, and Swiss investors following U.S.-listed healthcare names, BBIO remains a case study in the transition from innovation-driven biotech to emerging commercial pharma.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
